New drug combo aims to keep myeloma in check after transplant

NCT ID NCT02420860

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether adding elotuzumab to standard lenalidomide maintenance therapy can prevent multiple myeloma from returning after an autologous stem cell transplant. About 113 newly diagnosed patients who had a transplant will receive the combination. The goal is to see if the two drugs together extend the time before the cancer progresses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: elotuzumab and lenalidomide
What this could lead to: If it works, this combination could help keep multiple myeloma from coming back after a stem cell transplant, extending the time patients stay in remission.
What could go wrong: This is a mid-stage trial with 113 participants, so results are not yet conclusive. Adding elotuzumab may increase side effects without guaranteeing better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT PLASMA CELL MYELOMA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.